Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Taiho: Abraxan for Breast Cancer
August 2, 2010
- Pfizer to Begin PIII Trial for Selara for Chronic Heart Failure
August 2, 2010
- AZ: Pulmicort Inhaler for Asthma in Children
August 2, 2010
- RaQualia Begins PI Trial for APA in the US
August 2, 2010
- All Candidates from Nichiiren Fail to Obtain Seat in Upper House
July 26, 2010
- Iressa Doubles PFS in Japanese NSCLC Patients with Mutated EGFR
July 26, 2010
- Parliamentary Secretary for Health Shinya Adachi Reelected
July 26, 2010
- Kobayashi to Develop More Class 1 OTC Drugs
July 26, 2010
- Dr Fujii Regains Seat in Upper House
July 26, 2010
- JPA to Renew Its Efforts to Increase Members' Awareness of New OTC Drug Sales System
July 26, 2010
- Standardize Interpretation of 1980 Notification: Chuikyo
July 26, 2010
- Erbitux Associated with Fewer Severe Infusion Reactions in Japan
July 26, 2010
- Industry Criticized Again at Chuikyo Meeting
July 26, 2010
- Test for Predicting Efficacy of IFN Recommended for Approval as Advanced Technology
July 26, 2010
- Use of New Drugs Increasing in Cancer Therapy: CareNet
July 26, 2010
- Most Member Pharmacies Have Correctly Understood Significance of Premium: NPhA
July 26, 2010
- Nippon Chemiphar Aims at Sales of ¥30.0 Bil. with Generics in FY2012
July 26, 2010
- Interest Shown in Development of 3 More Unapproved Drugs
July 26, 2010
- Drug Market in Japan to Grow 3-6% in 2010-2014: IMS Japan
July 26, 2010
- Takeda Confident about Actos Data
July 26, 2010
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…